US 10500216
Optimizing mifepristone absorption
granted A61KA61K31/567A61K31/575
Quick answer
US patent 10500216 (Optimizing mifepristone absorption) held by Corcept Therapeutics Incorporated expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/567, A61K31/575